- Home
- BIOA
BIOA
BioAge Labs Inc. Common Stock
as 12-18-2024 2:32pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | $18.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -33.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.85 - $26.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioAge Labs Inc. Common Stock News
BIOA Breaking Stock News: Dive into BIOA Ticker-Specific Updates for Smart Investing
MT Newswires
5 hours ago
BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
GlobeNewswire
6 hours ago
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
Pharma Voice
2 days ago
3 closely watched drugs that failed in the clinic
Clinical Trials Arena
9 days ago
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
MT Newswires
9 days ago
Top Premarket Decliners
Benzinga
9 days ago
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
MT Newswires
9 days ago
Jefferies Downgrades BioAge Labs to Hold From Buy, Adjusts Price Target to $7 From $42
MT Newswires
9 days ago
Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45
Compare BIOA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIOA BioAge Labs Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.